Skip to main content
Premium Trial:

Request an Annual Quote

After Management Buyout, MRC s Genome Service Will Continue Commercially as Geneservice

NEW YORK, June 6 (GenomeWeb News) - Following a management buyout, MRC Geneservice, a provider of genomics reagents and services funded by the UK's Medical Research Council, will on Aug. 1 re-emerge as a commercial company called Geneservice, Cambridge, UK-based MRC Geneservice said today.

 

The new company will take over the assets and most of the staff of government-funded MRC Geneservice and will be based in the CambridgeSciencePark.

 

Geneservice will continue to archive and distribute genomic reagents, such as bacterial clones and human DNA samples generated by academic groups and consortia, and provide genomic services, such as DNA sequencing, genotyping, microarray expression analysis, and genome amplification.

 

In addition, the company plans to invest in new business opportunities, including resources such as RNAi and protein expression libraries.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.